Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

More documents

Recommendations

Info

11 References Mygind, N. and R. Dahl 1998 Anatomy, physiology and function of the nasal cavities in health and disease. Advanced Drug Delivery Reviews 29(1-2):3-12. NRF 2002 Rezepturhinweise: Midazolam-Rezepturen. Ono, N., F. Hirayama, H. Arima and K. Uekama 1999 Determination of stability constant of beta-cyclodextrin complexes using the membrane permeation technique and the permeation behavior of drug-competing agent-beta-cyclodextrin ternary systems. Eur J Pharm Sci 8(2):133-9. Pavis, H., A. Wilcock, J. Edgecombe, D. Carr, C. Manderson, A. Church and A. Fisher 2002 Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer. J Pain Symptom Manage 24(6):598-602. Penkler, L.J. 2001 Pharmaceutical composition containing midazolam. In PCT Int. Appl., 21 pp. WO: (Farmarc Nederland BV, Neth.). Quraishi, M.S., N.S. Jones and J. Mason 1998 The rheology of nasal mucus: a review. Clin Otolaryngol Allied Sci 23(5):403-13. Radomsky, A.S., S. Rachman, D.S. Thordarson, H.K. McIsaac and B.A. Teachman 2001 The Claustrophobia Questionnaire. J Anxiety Disord 15(4):287-97. Rahmel, D. 2004 Investigations of gene expression and metabolic activity of the human respiratory nasal mucosa. No pp given. Rajewski, R.A. and V.J. Stella 1996 Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery. Journal of Pharmaceutical Sciences 85(11):1142-1169. Reeuwijk, H.J., H. Irth, U.R. Tjaden, F.W. Merkus and J. van der Greef 1993 Liquid chromatographic determination of beta-cyclodextrin derivatives based on fluorescence enhancement after inclusion complexation. J Chromatogr 614(1):95-100. Rey, E., L. Delaunay, G. Pons, I. Murat, M.O. Richard, C. Saint-Maurice and G. Olive 1991 Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol 41(4):355-7. Roelofse, J., K. Payne, J. Morkel and L. Penkler 2000 Intranasal Midazolam Spray in Adults - pharmacokinetics and clinical use. The South African Journal of Anaesthesiology and Analgesia 6(2). Romeo, V.D., J. deMeireles, A.P. Sileno, H.K. Pimplaskar and C.R. Behl 1998 Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 29(1- 2):89-116. Rose, E., D. Simon and J.P. Haberer 1990 Premedication par midazolam intranasal en anesthesie pediatrique. [Premedication with intranasal midazolam in pediatric anesthesia]. Ann Fr Anesth Reanim 9(4):326-30. Saint-Maurice, C., A. Landais, M.M. Delleur, C. Esteve, K. MacGee and I. Murat 1990 The use of midazolam in diagnostic and short surgical procedures in children. Acta Anaesthesiol Scand Suppl 92:39-41; discussion 47. Sakane, T., M. Akizuki, M. Yoshida, S. Yamashita, T. Nadai, M. Hashida and H. Sezaki 1991 Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J Pharm Pharmacol 43(6):449-51. Salib, R.J. and P.H. Howarth 2003 Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 26(12):863-93. Scheepers, M., B. Scheepers, M. Clarke, S. Comish and M. Ibitoye 2000 Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy? Seizure 9(6):417-22. Katja Suter-Zimmermann Page 184 of 188 University of Basel, 2008
11 References Scheepers, M., B. Scheepers and P. Clough 1998 Midazolam via the intranasal route: an effective rescue medication for severe epilepsy in adults with learning disability. Seizure 7(6):509-12. Schipper, N.G., J.C. Verhoef and F.W. Merkus 1991 The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res 8(7):807-14. Schmidt, M.C., B. Rothen-Rutishauser, B. Rist, A. Beck-Sickinger, H. Wunderli-Allenspach, W. Rubas, W. Sadee and H.P. Merkle 1998 Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane. Biochemistry 37(47):16582-90. Schweizer, E., C. Clary, A.I. Dever and L.A. Mandos 1992 The use of low-dose intranasal midazolam to treat panic disorder: a pilot study. J Clin Psychiatry 53(1):19-22. Scott, R.C., F.M. Besag and B.G. Neville 1999 Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 353(9153):623-6. Scott, R.C., B.G. Neville, F.M. Besag and S.G. Boyd 1997 Nasal rather than rectal benzodiazepines in the management of acute childhood seizures? Dev Med Child Neurol 39(2):137-8. SEER's Web-based Training Module U.S. National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Programm; 2007.Available from http://training.seer.cancer.gov/module_anatomy/images/illu_nose_nasal_cavities.jpg Shahidi, F. and R. Abuzaytoun 2005 Chitin, chitosan, and co-products: chemistry, production, applications, and health effects. Adv Food Nutr Res 49:93-135. Soane, R.J., M. Frier, A.C. Perkins, N.S. Jones, S.S. Davis and L. Illum 1999 Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 178(1):55-65. Soane, R.J., M. Hinchcliffe, S.S. Davis and L. Illum 2001 Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 217(1-2):183-91. Sonja Böttcher, T.H.-T. 2000 Herstellung und Analytik eines Midazolam- und Ketamin-haltigen Nasensprays (Midaket-Nasenspray). Krankenhauspharmazie 21(12):618-621. Stella, V.J., V.M. Rao, E.A. Zannou and V. Zia 1999 Mechanisms of drug release from cyclodextrin complexes. Advanced Drug Delivery Reviews 36(1):3-16. Su, T., Z. Bao, Q.Y. Zhang, T.J. Smith, J.Y. Hong and X. Ding 2000 Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60(18):5074-9. Szente, L. and J. Szejtli 1999 Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Advanced Drug Delivery Reviews 36(1):17-28. Takeuchi, K., S. Suzuki and Y. Majima 2006 Morphological and functional changes of epithelial cells in allergic rhinitis. Clinical & Experimental Allergy Reviews 6(4):106-110. Tolksdorf, W., D. Bremerich and U. Nordmeyer 1989 Midazolam for premedication of infants. A comparison of the effect between oral and rectal administration. ANASTHESIE, INTENSIVTHERAPIE, NOTFALLMEDIZIN 24(6). Tolksdorf, W. and C. Eick 1991 Rectal, oral and nasal premedication using midazolam in children aged 1-6 years. A comparative clinical study. ANAESTHESIST 40(12). Torres-Lugo, M. and N.A. Peppas 2000 Transmucosal delivery systems for calcitonin: a review. Biomaterials 21(12):1191-6. Katja Suter-Zimmermann Page 185 of 188 University of Basel, 2008
Page 1:
TRANSMUCOSAL NASAL DRUG DELIVERY Sy
Page 5 and 6:
Acknowledgments At the Hospital Pha
Page 7:
Index EXPERIMENTAL SECTION 5 Projec
Page 11 and 12:
Summary Summary Transmucosal nasal
Page 13:
Summary Project III: In this random
Page 17:
THEORETICAL SECTION
Page 20 and 21:
1. Nasal drug delivery 1.2 Transmuc
Page 22 and 23:
1. Nasal drug delivery 1.3 Challeng
Page 25 and 26:
2. Impact of anatomy and physiology
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
3. Midazolam 3 Midazolam 3.1 Physic
Page 33 and 34:
3. Midazolam 3.2.1 Indications and
Page 35 and 36:
3. Midazolam Administration of high
Page 37 and 38:
3. Midazolam gastrointestinal tract
Page 39 and 40:
4. Compounding of nasal midazolam p
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49:
Page 53 and 54:
5. Project I: Development of prepar
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67:
Page 70 and 71:
6. Project II: Pharmacokinetic of t
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 91 and 92:
7. Project III: Transmucosal nasal
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103:
Page 106 and 107:
8 Overall discussion pharmacokineti
Page 108 and 109:
8 Overall discussion considered as
Page 111:
Appendix
Page 114 and 115:
10 Appendix 10.2 Project I 10.2.1 R
Page 116 and 117:
10 Appendix 10.2.4 Specification: M
Page 118 and 119:
10 Appendix 10.2.6 Specification: C
Page 120 and 121:
10 Appendix Katja Suter-Zimmermann
Page 122 and 123:
10 Appendix 10.2.9 Specification: C
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143: 10 Appendix Katja Suter-Zimmermann
Page 150 and 151: 10 Appendix 10.3.2 Case report form
Page 158 and 159: 10 Appendix Frequency 10.3.5 Intens
Page 160 and 161: 10 Appendix 10.3.7 Serumconcentrati
Page 162 and 163: 10 Appendix Identification midazola
Page 168 and 169: 10 Appendix 10.3.8 Midazolam serum
Page 170 and 171: 10 Appendix 10.3.10 Nasal delivery
Page 174 and 175: 10 Appendix 10.4.3 Flowchart: multi
Page 185 and 186: 11 References 11 References Abrams,
Page 187 and 188: 11 References Erjefalt, J.S., I. Er
Page 189 and 190: 11 References Irie, T. and K. Uekam
Page 191: 11 References Malinovsky, J.M., C.
Page 195 and 196: 12 Curriculum vitae 12 Curriculum v
show all

Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

Create successful ePaper yourself

Delete template?

Save as template?